Intermune Reports 1ST QTR 2010 Net Loss of $34.1 Million (Financial Report‪)‬

InterMune, Inc. (NASDAQ:ITMN), Brisbane, Calif., has announced results from operations for the first quarter ended March 31, 2010. InterMune also highlighted its recent clinical development and business activities, and previewed upcoming milestones in 2010. Dan Welch, Chairman, Chief Executive Officer and president of InterMune said, "First quarter and recent events have been highlighted by the very important developments related to the regulatory progress of pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis, or IPF. Our New Drug Application (NDA) for pirfenidone was granted Priority Review status on January 4, with a PDUFA action date of May 4, 2010. On March 9, an FDA advisory committee recommended 9-3 in favor of the approval of pirfenidone to reduce decline in lung function. If approved by the FDA, pirfenidone would be the first approved medicine for the approximately 100,000 Americans who suffer from this terrible disease. Regarding Europe, our Marketing Authorization Application (MAA) for pirfenidone in the European Union was validated on March 24, 2010."